Amylyx, faced with longer FDA path for promising ALS drug, gets major cash infusion
Bio Pharma Dive
JULY 20, 2021
A $135 million investment will help the small biotech potentially prepare to launch the treatment in Canada and Europe as well as fund another trial requested by U.S. regulators.
Let's personalize your content